relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   49 Trials   49 Trials   1092 News 


«12...45678910111213141516»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  LAG3-PD-1 Inhibitor Combo Impresses in Melanoma. (Pubmed Central) -  May 21, 2021   
    Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA4 have dramatically improved melanoma treatment-and the LAG3 immune checkpoint inhibitor relatlimab may soon be added to the mix. In a phase III trial, adding relatlimab to the PD-1 inhibitor nivolumab more than doubled progression-free survival, and the combination had relatively manageable side effects.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
    Enrollment change:  IMAGINE: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (clinicaltrials.gov) -  May 20, 2021   
    P2,  N=44, Recruiting, 
    In a phase III trial, adding relatlimab to the PD-1 inhibitor nivolumab more than doubled progression-free survival, and the combination had relatively manageable side effects. N=88 --> 44
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) -  May 17, 2021   
    P1,  N=18, Active, not recruiting, 
    N=88 --> 44 Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2021
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Tumor mutational burden:  NCI-2018-01517: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma (clinicaltrials.gov) -  May 14, 2021   
    P2,  N=20, Recruiting, 
    Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2021 Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Apr 2022
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Revlimid (lenalidomide) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. (Pubmed Central) -  May 1, 2021   
    Moreover, combination of LAG-3 with the immunomodulatory drug (IMiD) lenalidomide significantly increased IL-2 production by T cells and antibody-dependent cytotoxicity (ADCC) mediated by NK cells. Altogether, these data provide new insights into the potential anti-leukemic effects of relatlimab, currently in clinical trials in CLL, and provides the rationale to further investigate its combination with IMiDs for the management of hematological malignancies.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Enrollment closed, IO biomarker:  CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) -  Apr 8, 2021   
    P1,  N=32, Active, not recruiting, 
    Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Jul 2021 --> Apr 2022 Recruiting --> Active, not recruiting
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Enrollment closed, IO biomarker:  CA209-587: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin (clinicaltrials.gov) -  Mar 16, 2021   
    P2,  N=31, Active, not recruiting, 
    N=504 --> 295 | Active, not recruiting --> Terminated; The standard of care for the patient population changed and we were unable to accrue any longer. Recruiting --> Active, not recruiting
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial termination, Trial primary completion date:  Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (clinicaltrials.gov) -  Mar 5, 2021   
    P2,  N=2, Terminated, 
    Not yet recruiting --> Recruiting Trial completion date: Feb 2024 --> May 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> May 2020; Loss of funding
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, IO biomarker:  CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) -  Feb 12, 2021   
    P1,  N=25, Recruiting, 
    Trial completion date: Feb 2024 --> May 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> May 2020; Loss of funding Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2021 --> Feb 2022